Noteworthy Rebalancing AIDS efforts

WASHINGTON - NIH should restructure and refocus the federal AIDS drug discovery research effort, de-emphasizing the areas in which private industry is preeminent such as development of general AIDS therapies, and applying more resources to discovery of therapies for rare opportunistic infections and development of new screening methods, a high-level review of the NIH AIDS program has concluded.

More than 100 academic and industry scientists and community